Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 22, 2026 14:55 ET | Source: Spokane Dermatology Clinic

New Long-Term Data Shows Lebrikizumab Sustains Atopic Dermatitis Clearance With Less Frequent Dosing and Advances Findings from Dr. Philip Werschler of Spokane Dermatology Clinic

SPOKANE, Wash., June 22, 2026 (GLOBE NEWSWIRE) -- Long-term data shows that lebrikizumab [Ebglyss], an injectable treatment for moderate to severe atopic dermatitis, sustains gains for up to 2...